Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Home
/
update
/
details

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

NextEdge Admin

07 Jan 2025

2 min 7 sec

SunAct,Allogeneic Gamma Delta T Cell,Partnership

CytoMed Therapeutics Limited, a Singapore-based clinical-stage biopharmaceutical company specializing in allogeneic off-the-shelf immunotherapies, has announced a Business & Research Collaboration Agreement (BRCA) with Mumbai-based SunAct Cancer Institute Private Limited. This partnership aims to evaluate CytoMed’s proprietary allogeneic gamma delta T cells for treating various cancers, including solid tumors, through clinical research in India.

Under the agreement, CytoMed and SunAct will jointly sponsor a Phase 2 investigator-initiated clinical trial, led by renowned oncologist and immunotherapy specialist Prof. Dr. Vijay Patil. The trial will assess the safety, tolerability, potency, and efficacy of gamma delta T cells, expediting data collection on their clinical application, side effects, and optimal dosing.

Dr. Vijay Patil emphasized the trial's potential to identify cancer types responsive to the therapy while ensuring accessibility and affordability for Indian patients. He highlighted the importance of expanding global immunotherapy data. CytoMed’s Chairman, Peter Choo, underscored the collaboration’s alignment with CytoMed’s mission to develop cost-effective, donor-derived immunotherapies, enhancing cancer treatment options worldwide.

CytoMed will provide scientific and technical support for the trial and manufacture the investigational product. SunAct, leveraging its regulatory expertise and local networks, will facilitate trial execution. Supported by India's commitment to advancing cancer immunotherapy this collaboration aims to accelerate innovative, affordable cancer treatments for a broader patient population in India and beyond.